Results 211 to 220 of about 685,834 (309)

Efficacy of Ritlecitinib for Vitiligo Treatment Stratified by Baseline Demographic and Clinical Characteristics: Post Hoc Analysis of a Phase 2b Study

open access: yesJEADV Clinical Practice, EarlyView.
This post hoc analysis examined the efficacy of ritlecitinib in subgroups of patients with vitiligo, defined by demographic and clinical characteristics. Patients completed the dose‐ranging and extension periods of the phase 2b study (NCT03715829) of ritlecitinib.
A. G. Pandya   +8 more
wiley   +1 more source

First Report of Homozygous COL7A1 c.5756delG Mutation Causing Recessive Dystrophic Epidermolysis Bullosa in a Non‐Consanguineous Japanese Family

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Severe recessive dystrophic epidermolysis bullosa (RDEB) is usually caused by biallelic loss‐of‐function mutations in COL7A1. While the c.5756delG variant has been previously reported in heterozygous form, its clinical impact in homozygosity has not been described.
Nozomi Kohama   +6 more
wiley   +1 more source

Menthol-Based Cream as a Novel Therapy for Diabetic Skin Wounds. [PDF]

open access: yesPharmaceutics
Vieira AJ   +7 more
europepmc   +1 more source

Clinical Efficacy and Safety of Topical Roflumilast in Psoriasis: An Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Traditional first‐line topical treatments for plaque psoriasis, particularly corticosteroids and vitamin D analogs, frequently have only limited efficacy for long‐term use, and present difficulties with safety and adherence. Objectives In this systematic review and meta‐analysis of randomized controlled trials (RCTs), we assessed ...
Aimal A. Khattak   +11 more
wiley   +1 more source

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy